Clinical Trials Logo
  1. Home
  2. Hyperglucagonemia
  3. NCT01436734

Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125

Hyperglucagonemia Clinical Trial

Clinical Trial Summary

The aim of the study was to investigate the role of the Trasylol in glucagon prevention in degradation using radioimmunoactive method with I125. Additionally different incubation time was introduced in human plasma samples after oral glucose stimulation, also in fasted and hypoglycemia blood samples from patients' type 2 diabetes. Since, the structure and the techniques for the glucagon measurement are well described nowadays.

Clinical Trial Description

n/a

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01436734
Study type Interventional
Source University Hospital, Gentofte, Copenhagen
Contact
Status Completed
Phase N/A
Start date July 2011
Completion date May 2013
View Details
See also
  Status Clinical Trial Phase
Completed NCT02237053 - Effects of Glucagon Administration on Energy Expenditure Phase 1
Completed NCT00862589 - Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM) N/A
Active, not recruiting NCT00704795 - Glucagon Responses During Oral- and iv Glucose in Patients With Type 1 Diabetes N/A
Completed NCT05056584 - The Role of the Kidneys and Liver in the Elimination of Glucagon N/A